Non-ischemic cardiomyopathies (NICM) represent a heterogeneous group of pathologies characterized by absence of obstructive disease of the epicardial coronary vessels and distinct structural and functional changes of the myocardium. The main identified forms include dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic cardiomyopathy proper (ACM). More recently, further forms of cardiomyopathy have been described, less common and not uniquely classifiable, including: uncompressed myocardium (LVNC), peripartum cardiomyopathy (PPCM), structural correlates of arrhythmogenic mitral valve prolapse (AMVP), Anderson-Fabry disease (AFD), NICM associated with multi- system neuromuscular or autoimmune diseases, lysosomal diseases, glycogenosis, mitochondrial cytopathies and canal diseases with structural substrates. Finally, there are "overlap" forms, characterized by the sharing in the same subject of characteristic aspects of two or more of the above- mentioned diseases; and of the "undefined" forms, which to date do not reach the diagnostic criteria for any of the above-mentioned diseases. To the best of current knowledge, there are two points discovered in scientific research, namely the description of the arrhythmogenic and "inflammatory" phenotypes in a broad sense, which are summarized here with the acronym AINICM. In detail: 1. Arrhythmic manifestations account for the arrhythmogenic component of AINICM, which is not limited to ACM proper. In fact, most of the above diseases have a non-arrhythmic clinical presentation and a prevailing tendency to evolve towards a picture of cardiovascular decompensation. Although sudden arrhythmic death has been described throughout the spectrum of AINICM, early arrhythmic manifestations of such diseases have an unknown prevalence, an uncertain association with different disease genotypes and phenotypes, and still uncertain predictivity of long-term arrhythmic risk. At the same time, optimal diagnostic and therapeutic pathways in arrhythmias associated with AINICM are still being studied. 2. Myocardial inflammation (M-Infl) accounts for the inflammatory component of AINICM, and has recently been described in association with many AINICM on a genetic basis, including undefined and arrhythmic forms. The data is of high interest not only in the diagnostic, but also in prognostic and therapeutic field. In fact, on the one hand the presence of M-Infl seems to have a physio- pathological role in AINICM; on the other, as already known in myocarditis, the optimal therapeutic paths of arrhythmias may differ in patients with and without M-Infl; in particular, also in the light of the preliminary data available in adult and paediatric AINICM, the inflammatory forms are expected to respond better to immunosuppressive therapy, the arrhythmogenic ones to an ablative therapy with frequent need of implantation of cardiac devices. Based on the clinical presentation, NICM patients will be divided into arrhythmic (AINICM) and non-arrhythmic patients as study and control groups , respectively. The AINICM group will include presentation with ventricular fibrillation (VF), either sustained or non-sustained ventricular tachycardia (VT; NSVT), frequent premature ventricular complexes (PVC), supraventricular arrhythmias (SVA) and bradyarrhythmias (BA). Clinical presentations other than arrhythmic, including chest pain and heart failure, will define the control group. In parallel, as shown in Figure 1, patients with any evidence of M-Infl will be compared with those showing no signs of M-Infl.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Timeframe: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Timeframe: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Timeframe: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Timeframe: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Timeframe: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Timeframe: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Timeframe: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Timeframe: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Timeframe: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Timeframe: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Timeframe: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Timeframe: At year 30
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Timeframe: At baseline
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Timeframe: At year 5
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Timeframe: At year 10
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Timeframe: At year 15
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Timeframe: At year 20
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Timeframe: At year 25
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Timeframe: At year 30
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 30
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At baseline
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 5
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 10
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 15
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 20
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 25
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Timeframe: At year 30
Identification of DCM-specific signatures
Timeframe: At baseline
Identification of DCM-specific signatures
Timeframe: At year 5
Identification of DCM-specific signatures
Timeframe: At year 10
Identification of DCM-specific signatures
Timeframe: At year 15
Identification of DCM-specific signatures
Timeframe: At year 20
Identification of DCM-specific signatures
Timeframe: At year 25
Identification of DCM-specific signatures
Timeframe: At year 30
Identification of HCM-specific signatures
Timeframe: At baseline
Identification of HCM-specific signatures
Timeframe: At year 5
Identification of HCM-specific signatures
Timeframe: At year 10
Identification of HCM-specific signatures
Timeframe: At year 15
Identification of HCM-specific signatures
Timeframe: At year 20
Identification of HCM-specific signatures
Timeframe: At year 25
Identification of HCM-specific signatures
Timeframe: At year 30
Identification of RCM-specific signatures
Timeframe: At baseline
Identification of RCM-specific signatures
Timeframe: At year 5
Identification of RCM-specific signatures
Timeframe: At year 10
Identification of RCM-specific signatures
Timeframe: At year 15
Identification of RCM-specific signatures
Timeframe: At year 20
Identification of RCM-specific signatures
Timeframe: At year 25
Identification of RCM-specific signatures
Timeframe: At year 30
Identification of ACM-specific signatures
Timeframe: At baseline
Identification of ACM-specific signatures
Timeframe: At year 5
Identification of ACM-specific signatures
Timeframe: At year 10
Identification of ACM-specific signatures
Timeframe: At year 15
Identification of ACM-specific signatures
Timeframe: At year 20
Identification of ACM-specific signatures
Timeframe: At year 25
Identification of ACM-specific signatures
Timeframe: At year 30
Identification of LVNC-specific signatures
Timeframe: At baseline
Identification of LVNC-specific signatures
Timeframe: At year 5
Identification of LVNC-specific signatures
Timeframe: At year 10
Identification of LVNC-specific signatures
Timeframe: At year 15
Identification of LVNC-specific signatures
Timeframe: At year 20
Identification of LVNC-specific signatures
Timeframe: At year 25
Identification of LVNC-specific signatures
Timeframe: At year 30
Identification of AMVP-specific signatures
Timeframe: At baseline
Identification of AMVP-specific signatures
Timeframe: At year 5
Identification of AMVP-specific signatures
Timeframe: At year 10
Identification of AMVP-specific signatures
Timeframe: At year 15
Identification of AMVP-specific signatures
Timeframe: At year 20
Identification of AMVP-specific signatures
Timeframe: At year 25
Identification of AMVP-specific signatures
Timeframe: At year 30
Identification of PPCM-specific signatures
Timeframe: At baseline
Identification of PPCM-specific signatures
Timeframe: At year 5
Identification of PPCM-specific signatures
Timeframe: At year 10
Identification of PPCM-specific signatures
Timeframe: At year 15
Identification of PPCM-specific signatures
Timeframe: At year 20
Identification of PPCM-specific signatures
Timeframe: At year 25
Identification of PPCM-specific signatures
Timeframe: At year 30
Identification of AFD-specific signatures
Timeframe: At baseline
Identification of AFD-specific signatures
Timeframe: At year 5
Identification of AFD-specific signatures
Timeframe: At year 10
Identification of AFD-specific signatures
Timeframe: At year 15
Identification of AFD-specific signatures
Timeframe: At year 20
Identification of AFD-specific signatures
Timeframe: At year 25
Identification of AFD-specific signatures
Timeframe: At year 30
Identification of storage and dysmetabolic diseases-specific signatures
Timeframe: At baseline
Identification of storage and dysmetabolic diseases-specific signatures
Timeframe: At year 5
Identification of storage and dysmetabolic diseases-specific signatures
Timeframe: At year 10
Identification of storage and dysmetabolic diseases-specific signatures
Timeframe: At year 15
Identification of storage and dysmetabolic diseases-specific signatures
Timeframe: At year 20
Identification of storage and dysmetabolic diseases-specific signatures
Timeframe: At year 25
Identification of storage and dysmetabolic diseases-specific signatures
Timeframe: At year 30
Identification of mitochondrial diseases-specific signatures
Timeframe: At baseline
Identification of mitochondrial diseases-specific signatures
Timeframe: At year 5
Identification of mitochondrial diseases-specific signatures
Timeframe: At year 10
Identification of mitochondrial diseases-specific signatures
Timeframe: At year 15
Identification of mitochondrial diseases-specific signatures
Timeframe: At year 20
Identification of mitochondrial diseases-specific signatures
Timeframe: At year 25
Identification of mitochondrial diseases-specific signatures
Timeframe: At year 30
Identification of channelopathies with structural changes-specific signatures
Timeframe: At baseline
Identification of channelopathies with structural changes-specific signatures
Timeframe: At year 5
Identification of channelopathies with structural changes-specific signatures
Timeframe: At year 10
Identification of channelopathies with structural changes-specific signatures
Timeframe: At year 15
Identification of channelopathies with structural changes-specific signatures
Timeframe: At year 20
Identification of channelopathies with structural changes-specific signatures
Timeframe: At year 25
Identification of channelopathies with structural changes-specific signatures
Timeframe: At year 30
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Timeframe: At baseline
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Timeframe: At year 5
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Timeframe: At year 10
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Timeframe: At year 15
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Timeframe: At year 20
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Timeframe: At year 25
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Timeframe: At year 30
Identification of overlapping phenotypes-specific signatures
Timeframe: At baseline
Identification of overlapping phenotypes-specific signatures
Timeframe: At year 5
Identification of overlapping phenotypes-specific signatures
Timeframe: At year 10
Identification of overlapping phenotypes-specific signatures
Timeframe: At year 15
Identification of overlapping phenotypes-specific signatures
Timeframe: At year 20
Identification of overlapping phenotypes-specific signatures
Timeframe: At year 25
Identification of overlapping phenotypes-specific signatures
Timeframe: At year 30
Identification of undefined phenotypes-specific signatures
Timeframe: At baseline
Identification of undefined phenotypes-specific signatures
Timeframe: At year 5
Identification of undefined phenotypes-specific signatures
Timeframe: At year 10
Identification of undefined phenotypes-specific signatures
Timeframe: At year 15
Identification of undefined phenotypes-specific signatures
Timeframe: At year 20
Identification of undefined phenotypes-specific signatures
Timeframe: At year 25
Identification of undefined phenotypes-specific signatures
Timeframe: At year 30
Differences in incidence of major events during follow-up in different NICMs
Timeframe: At baseline
Differences in incidence of major events during follow-up in different NICMs
Timeframe: At year 5
Differences in incidence of major events during follow-up in different NICMs
Timeframe: At year 10
Differences in incidence of major events during follow-up in different NICMs
Timeframe: At year 15
Differences in incidence of major events during follow-up in different NICMs
Timeframe: At year 20
Differences in incidence of major events during follow-up in different NICMs
Timeframe: At year 25
Differences in incidence of major events during follow-up in different NICMs
Timeframe: At year 30
Occurrence of major cardiac events in DCM
Timeframe: At 10 years
Occurrence of major cardiac events in DCM
Timeframe: At 1 year
Occurrence of major cardiac events in DCM
Timeframe: At 3 years
Occurrence of major cardiac events in DCM
Timeframe: At 5 years
Occurrence of major cardiac events in DCM
Timeframe: At 15 years
Occurrence of major cardiac events in DCM
Timeframe: At 20 years
Occurrence of major cardiac events in DCM
Timeframe: At 25 years
Occurrence of major cardiac events in DCM
Timeframe: At 30 years
Occurrence of major cardiac events in HCM
Timeframe: At 1 year
Occurrence of major cardiac events in HCM
Timeframe: At 3 years
Occurrence of major cardiac events in HCM
Timeframe: At 5 years
Occurrence of major cardiac events in HCM
Timeframe: At 10 years
Occurrence of major cardiac events in HCM
Timeframe: At 15 years
Occurrence of major cardiac events in HCM
Timeframe: At 20 years
Occurrence of major cardiac events in HCM
Timeframe: At 25 years
Occurrence of major cardiac events in HCM
Timeframe: At 30 years
Occurrence of major cardiac events in RCM
Timeframe: At 1 year
Occurrence of major cardiac events in RCM
Timeframe: At 3 years
Occurrence of major cardiac events in RCM
Timeframe: At 5 years
Occurrence of major cardiac events in RCM
Timeframe: At 10 years
Occurrence of major cardiac events in RCM
Timeframe: At 15 years
Occurrence of major cardiac events in RCM
Timeframe: At 20 years
Occurrence of major cardiac events in RCM
Timeframe: At 25 years
Occurrence of major cardiac events in RCM
Timeframe: At 30 years
Occurrence of major cardiac events in ACM
Timeframe: At 1 year
Occurrence of major cardiac events in ACM
Timeframe: At 3 years
Occurrence of major cardiac events in ACM
Timeframe: At 5 years
Occurrence of major cardiac events in ACM
Timeframe: At 10 years
Occurrence of major cardiac events in ACM
Timeframe: At 15 years
Occurrence of major cardiac events in ACM
Timeframe: At 20 years
Occurrence of major cardiac events in ACM
Timeframe: At 25 years
Occurrence of major cardiac events in ACM
Timeframe: At 30 years
Occurrence of major cardiac events in LVNC
Timeframe: At 1 year
Occurrence of major cardiac events in LVNC
Timeframe: At 5 years
Occurrence of major cardiac events in LVNC
Timeframe: At 10 years
Occurrence of major cardiac events in LVNC
Timeframe: At 30 years
Occurrence of major cardiac events in AMVP
Timeframe: At 1 year
Occurrence of major cardiac events in AMVP
Timeframe: At 5 years
Occurrence of major cardiac events in AMVP
Timeframe: At 10 years
Occurrence of major cardiac events in AMVP
Timeframe: At 30 years
Occurrence of major cardiac events in PPCM
Timeframe: At 1 year
Occurrence of major cardiac events in PPCM
Timeframe: At 5 years
Occurrence of major cardiac events in PPCM
Timeframe: At 10 years
Occurrence of major cardiac events in PPCM
Timeframe: At 30 years
Occurrence of major cardiac events in AFD
Timeframe: At 1 year
Occurrence of major cardiac events in AFD
Timeframe: At 5 years
Occurrence of major cardiac events in AFD
Timeframe: At 10 years
Occurrence of major cardiac events in AFD
Timeframe: At 30 years
Occurrence of major cardiac events in storage and dysmetabolic diseases
Timeframe: At 1 year
Occurrence of major cardiac events in storage and dysmetabolic diseases
Timeframe: At 5 years
Occurrence of major cardiac events in storage and dysmetabolic diseases
Timeframe: At 10 years
Occurrence of major cardiac events in storage and dysmetabolic diseases
Timeframe: At 30 years
Occurrence of major cardiac events in mitochondrial diseases
Timeframe: At 1 year
Occurrence of major cardiac events in mitochondrial diseases
Timeframe: At 5 years
Occurrence of major cardiac events in mitochondrial diseases
Timeframe: At 10 years
Occurrence of major cardiac events in mitochondrial diseases
Timeframe: At 30 years
Occurrence of major cardiac events in channelopathies with structural changeschannelopathies with structural changes
Timeframe: At 1 year
Occurrence of major cardiac events in channelopathies with structural changes
Timeframe: At 5 years
Occurrence of major cardiac events in channelopathies with structural changes
Timeframe: At 10 years
Occurrence of major cardiac events in channelopathies with structural changes
Timeframe: At 30 years
Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At 1 year
Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At 5 years
Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At 10 years
Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At 30 years
Occurrence of major cardiac events in overlapping phenotypes
Timeframe: At 1 year
Occurrence of major cardiac events in overlapping phenotypes
Timeframe: At 5 years
Occurrence of major cardiac events in overlapping phenotypes
Timeframe: At 10 years
Occurrence of major cardiac events in overlapping phenotypes
Timeframe: At 30 years
Occurrence of major cardiac events in undefined phenotypes
Timeframe: At 1 year
Occurrence of major cardiac events in undefined phenotypes
Timeframe: At 5 years
Occurrence of major cardiac events in undefined phenotypes
Timeframe: At 10 years
Occurrence of major cardiac events in undefined phenotypes
Timeframe: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Timeframe: At 30years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Timeframe: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Timeframe: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Timeframe: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Timeframe: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Timeframe: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Timeframe: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Timeframe: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Timeframe: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Timeframe: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Timeframe: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Timeframe: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Timeframe: At 30 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Timeframe: At baseline
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Timeframe: At 5 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Timeframe: At 10 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Timeframe: At 15 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Timeframe: At 20 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Timeframe: At 25 years
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Timeframe: At 30 years